James Simsarian, MD
Neurology · Fairfax, VANPI 1235108986
Payments from drug & device makers
Across 283 payments — averaging $611.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$59K
- Biogen$51K
- Sanofi$24K
- Novartis$21K
- Bristol Myers Squibb$16K
- Teva Pharmaceuticals USA, Inc.$284
- plus $1K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 60 | $59,440 |
| Biogen | 80 | $51,439 |
| Sanofi | 30 | $24,293 |
| Novartis | 46 | $20,572 |
| Bristol Myers Squibb | 22 | $15,868 |
| Teva Pharmaceuticals USA, Inc. | 4 | $284 |
| Lilly USA, LLC | 2 | $144 |
| EMD Serono, Inc. | 4 | $140 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Amgen(2 entities) | 3 | $82 |
| TG Therapeutics, Inc. | 3 | $71 |
| AstraZeneca | 3 | $69 |
| AbbVie | 3 | $63 |
| Supernus Pharmaceuticals, Inc. | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Banner Life Sciences, LLC | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| UCB, Inc. | 2 | $32 |
| Argenx US, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| GE HealthCare | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Adamas Pharmaceuticals, Inc. | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $13 |
How this compares
$173,013 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Fairfax
- Rahul DaveFairfax$1M
- John RothrockFairfax$504K
- Laura CinskiFairfax$124K
- Abigail LawlerFairfax$107K
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
- Simon FishmanAlexandria$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.